Australasian PsychiatryMarch 31, 2026Shuichi Suetani, Faraz Honarparvar, Peter Muller et al.
Background Given that both attention-deficit hyperactivity disorder (ADHD) and cannabis use are known independent risk factors for psychosis, people with ADHD who consume cannabis may be especially vulnerable. The main objective of the current study was to explore the links between ADHD, cannabis use and psychosis outcomes. Methods A systematic review was conducted to examine the risk of...
Little is known about whether 3,4-methylenedioxy-N-methamphetamine (MDMA) neurocognitive side effects improve with sustained abstinence. This study aimed to systematically review and synthesise the existing literature on the long-term neurocognitive side effects of recreational MDMA use after a minimum of 6 months of abstinence. We searched relevant databases utilising terms related to (1) MDMA...
Despite recent clinical and research interest, medical use of psychedelics has not been legalised in most jurisdictions. The Australian Therapeutic Goods Administration rescheduled methylenedioxymethamphetamine (MDMA) in July 2023 to permit authorised prescribing of MDMA for Post-traumatic Stress Disorder (PTSD) outside of the clinical trial setting. This manuscript describes the development of...
Background: Recent regulatory changes in Australia have approved 3,4-methylenedioxymethamphetamine for treating post-traumatic stress disorder and psilocybin for treatment-resistant depression. However, limited data exists on Australian mental healthcare providers’ attitudes, knowledge and readiness to implement with psychedelic-assisted psychotherapy. Methods: A cross-sectional survey was...
BMJ OpenApril 1, 2025Vanessa L. Beesley, Tom Kennedy, Fiona Maccallum et al.2 citations
Introduction Prolonged grief disorder (PGD) represents a substantial public health issue, especially in oncology settings where it affects up to 30% of bereaved carers. Current best-practice treatments are lengthy, and up to 50% of participants have persistent PGD. Building on encouraging recent research with psychedelic-assisted therapies, the Psilocybin-Assisted suppoRtive psychoTherapy IN...
Despite rapid advances in psychedelic sciences and the increasing number of countries legalizing psychedelics for the treatment of mental illnesses, the attitudes, knowledge and readiness of both mental health consumers and the general population remain largely unknown. A cross-sectional survey was conducted among Australians, targeting individuals with mental illness as potential mental health...
Since its introduction to the West in 1969 by Swāmī Rāma through experiments conducted at the U.S. Menninger Foundation, yoga-nidrā has become a popular practice among yoga teachers from many traditions. The result is a patchwork of techniques incorporating a variety of practices and procedures. It has come to be thought of primarily as technique and the variability of techniques across...
The study of consciousness within cognitive neuroscience has been dominated in recent years by investigations originating from collaborations between neuroscientific investigators and Buddhist meditation practitioners. The results have been remarkable, particularly when quantitative and qualitative research methods have been combined as they are in the neurophenomenological methodology...
Background: The therapeutic use of 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin has gained interest due to their potential efficacy in treating mental illness. We systematically reviewed the efficacy of MDMA and psilocybin in treating mental illness and explored the moderating effects of dosage, psychotherapeutic support, and concurrent antidepressant use. Methods: In this systematic...